Overview
Myosclerosis refers to the hardening and loss of elasticity in muscle tissue, often associated with reduced muscle quality and quantity. This condition can impact muscle function and is linked to various geriatric and chronic diseases 1.Diagnosis
Serum Biomarkers: Creatinine-to-cystatin C ratio (CCR) may serve as a non-invasive marker for assessing skeletal muscle health.
Imaging: Computed tomography (CT) measures such as skeletal muscle index (SMI) and skeletal muscle density (SMD) are useful for evaluating muscle quantity and quality 1.Management
Monitoring Biomarkers: Regular assessment of CCR can help monitor changes in muscle health over time.
Multifactorial Approach: Exercise interventions and nutritional support are recommended to improve muscle quality and quantity, though specific drug treatments are not detailed in the provided abstracts 1.Special Populations
Elderly: CCR and CT measures may be particularly relevant for assessing muscle health in elderly populations, given the prognostic value in geriatric care 1.Key Recommendations
Utilize the creatinine-to-cystatin C ratio (CCR) as a serum-based marker to assess skeletal muscle quantity and potential risk of myosteatosis in clinical settings (Evidence: Moderate 1).
Incorporate computed tomography (CT) assessments of skeletal muscle index (SMI) and density (SMD) for comprehensive evaluation of muscle health in patients at risk for myosclerosis (Evidence: Moderate 1).
Consider multifactorial management strategies including exercise and nutrition to support muscle health, particularly in elderly patients (Evidence: Expert opinion 1).References
1 Mirzai S, Bancks MP, Brinkley TE, Carbone S, Tang WHW, Allison MA et al.. Association of creatinine-to-cystatin C ratio with computed tomography measures of skeletal muscle quantity and quality: The multi-ethnic study of atherosclerosis. Clinical nutrition (Edinburgh, Scotland) 2025. link